Earnings Call Live Updates

Total Income increased to ₹45.94 Lacs from ₹23.44 Lacs YoY.

Net Loss decreased to ₹66.23 Lacs from ₹380.63 Lacs YoY.

Company is facing severe financial stress, raising doubts about asset realization.

Auditor notes the company did not maintain accounting software with audit trail feature.

The company has outstanding loans and advances of ₹96.48 Lacs.

Revenue from operations stood at ₹95.46 Lacs for FY25.

Net loss after tax was ₹8748.86 Lacs for FY25.

The company's restructuring is under consideration by lenders, with TEV studies conducted.

Auditors issued a qualified opinion due to going concern uncertainties.

The company has deposited ₹705.00 Lacs with bankers for settling dues.

There are arrears of undisputed statutory dues amounting to ₹1,209.07 Lacs and ₹66.56 Lacs respectively.

The company is recognizing deferred tax assets on losses, with management expecting future profits to setoff these losses.

Current liabilities exceed current assets.

AUM grew by 74% year-on-year, indicating strong growth trajectory.

PAT and net profit margin reflect a focus on profitability and sustainable growth.

New digital lending guidelines provide clarity and a clear path for growth.

Shift towards retail loans is planned, targeting a 70% retail and 30% term loan mix.

Emphasis on thorough due diligence of LSPs and caution regarding high debt-to-equity exposures.

The company is leveraging technology, including AI, to improve operational efficiency and compliance.

Term loan interest rates are between 16-17% and upwards.

The company is focusing on building a strong foundation for sustainable growth, prioritizing quality over rapid expansion.

Consolidated revenue grew by 27.5% YoY to ₹1,407 crore.

EBITDA increased by 14.9% YoY to ₹200 crore.

Capacity utilization improved to 85% in FY25.

Plans to expand Sri Lanka operations to 2,000 machines by FY27, targeting ₹400 crore revenue.

SPUK revenue reached GBP 5.22 million with a GBP 4.5 million order book.

Retail division reported revenue of ₹79.4 crore with ongoing efforts to improve profitability.

Standalone adjusted revenue for FY25 stood at ₹984 crore with an EBITDA of ₹164 crore and PAT of ₹83.5 crore.

Gross debt on a standalone basis stood at ₹235 crore, with net debt at ₹205 crore.

Q4 FY25 revenue increased by 4% QoQ to ₹264 crore.

EBITDA increased by 7% QoQ to ₹87 crore.

PAT increased by 8% QoQ to ₹53 crore.

EPS increased from ₹17 to ₹18 per share.

FY25 revenue increased by 37% YoY to ₹884 crore.

EBITDA increased by 19% YoY to ₹237 crore.

PAT increased by 24% YoY to ₹141 crore.

Gross debt reduced from ₹282 crore to ₹139 crore YoY.

Net cash position improved from ₹51 crore to ₹131 crore YoY.

Acquisition of Rig Jindal Pioneer contributed to revenue and EBITDA growth.

Consolidated revenue increased by 5% YoY to ₹3,060 crore in Q4 FY25.

Lead Acid Battery business grew by 4% YoY, contributing ₹2,900 crore.

New Energy Business revenue increased by 35% YoY.

Export volumes decreased by 10% YoY due to muted demand in Western and APAC regions.

Margin compression of 1.5-2% due to higher material and power costs.

FY25 revenue grew by 10% YoY.

Capex spend was ₹1200 crore, allocated to lead acid and new energy businesses.

Targeting a 14% margin through cost mitigation and throughput enhancement.

Lead acid recycling plant commenced commercial operations in Q4.

Expects to add 6 million battery capacity without significant additional capex.

FY25 revenue increased by 16% YoY to ₹4,784 crore.

FY25 net profit increased by 36% YoY to ₹1,883.4 crore.

Company anticipates a 20% revenue dip and 30% profit dip in FY26.

Strong cash position of over ₹3,500 crore.

₹50 crore impairment charge in Crop Health Science business.

Risdiplam litigation outcome expected in June 2025; launch possible immediately if favorable.

NRC-2694 trial ongoing in the US and India, with potential clarity in 1-1.5 years.

Semaglutide launch expected by the end of FY26.

R&D expenditure targeted at approximately ₹400 crore for FY26.

Domestic business expected to grow, driven by Risdiplam and Semaglutide launches.

Revenue from continuing operations grew by 6.7% YoY to ₹1,988 crore.

Adjusted EBITDA margin improved to 9.5% from 8.3% in FY24.

Strategic investment in Jean Dousset Jewelry LLC to grow branded business.

Cost optimization program launched, projected to deliver annual savings of ₹40-50 crore.

Closure of Bhavnagar facility will result in annual savings of ₹20 crore.

Net debt declined to ₹250 crore, with a net debt to equity ratio of 0.18.

Cash and bank balances along with current investments stood at ₹265 crore.

Plans to increase the physical footprint of Jean Dousset with a new flagship location in New York City.

Launched Wonder Fine Jewelry, a new umbrella brand encompassing Star Wars, Disney, Jewels and Marvel.

Total income for FY25 was ₹4,958 crore, with an EBITDA margin of 16.4%.

Political uncertainty lengthened the sales cycle, prompting a focus on smaller projects.

HGS is heavily investing in AI through its Agent X platform and AI Labs.

The company is expanding digital operations with new centers in Bengaluru and Cape Town.

Broadband business ARPUs remain steady at ₹179 per month.

Strategic focus includes growing the retail organic subscriber base and expanding CelerityX.

The company is transitioning towards a higher proportion of digital revenue in its BPM business.

The company is focused on cost savings and rationalization to improve profitability.

The company is leveraging its existing DTV customer base to sell other services like broadband.

Revenue from operations decreased from ₹695.73 lakhs in FY24 to ₹673.96 lakhs in FY25.

Net loss after tax significantly decreased from a profit of ₹19.74 lakhs in FY24 to a loss of ₹70.87 lakhs in FY25.

Cash flow from operating activities was negative at -₹62.20 lakhs.

Total expenses increased from ₹686.47 lakhs in FY24 to ₹743.29 lakhs in FY25.

The company's total assets stand at ₹1428.42 lakhs, while total equity is ₹482.85 lakhs.

Highest ever revenue of ₹976 crore and EBITDA of ₹368 crore achieved in FY'25.

Completed refurbishment of Grand Hyatt Mumbai, enhancing revenue streams.

Acquired one Greenfield and one Brownfield project, adding 335 keys.

Plans to add 2,072 keys in the next 3 years through strategic projects.

Strong balance sheet with a debt-equity ratio of 0.3 and ₹2,900 crore headroom for growth.

Q4 saw a corporate EBITDA margin of 44%, driven by strong asset performance.

ARR grew by 8% overall, with Delhi and Mumbai as star performers.

PBT of ₹150 crore achieved in FY'25, with ₹74 crore in Q4.

Net bank debt-to-EBITDA is under 1.5x, providing significant growth headroom.

Consolidated revenue increased by 13% YoY, driven by strong performance in the Plywood and MDF segments.

Plywood segment achieved a 9.8% YoY revenue growth with a healthy EBITDA margin of 15.4%.

MDF segment revenue grew significantly by 37.5%, with the Andhra Pradesh facility achieving EBITDA positivity.

Laminate segment faced margin pressure due to higher schemes and increased sales overhead.

Particle Board segment experienced a revenue decline of 23.2% due to market pressures.

New Tamil Nadu plant expected to improve EBITDA margin due to lower production costs.

Expects 20% growth and 8-10% EBITDA margin towards the end of H2.

Targeting INR12,000 crore turnover by FY31.

Revenue grew over 30% YoY, EBITDA increased over 20% YoY.

Operating cash flow of INR1,496 million with a cash conversion ratio of around 70%.

Greater Faridabad facility contributed INR436 million in revenues within 10 months.

Two new hospitals in Delhi and Faridabad are expected to be operationalized soon.

Group ARPOB rose by 7% to INR31,441, with Noida Extension reporting the highest ARPOB at INR38,806.

EBITDA for FY25 stood at INR2,202 million, up 22% Y-o-Y with an EBITDA margin of 25%.

Net profit for the period stood at INR1,306 million, up 14% Y-o-Y.

Net cash position of INR5,032 million, bolstered by the recent QIP.

AKS Medical has deposited INR12.38 million as additional tax, marking a step forward in the resolution process.

Company is intensifying focus on attracting medical value travel.

Revenue grew 14% QoQ and 35% YoY in Q4 FY25, indicating a recovery after difficult previous quarters.

PBT reached a record ₹208 crore for the quarter.

Margins were under pressure due to commodity volatility and changes in product mix.

E-beam products launched with a potential revenue of ₹500-600 crore per year.

BharatNet bids were unsuccessful, but discussions are ongoing with winners for potential business.

Project sales now constitute a larger portion of the mix (8-10% increase), affecting pricing.

Optic fiber cable prices have seen a recent increase from $2.5 to $3.5 per kilometer.

EHV segment shows strong growth potential, with market size expected to reach $1.5-2 billion in 4-5 years.

Revenue from operations declined by 1.2% YoY to ₹788 crore.

Gross margin eroded by 230 bps YoY.

EBITDA margin decreased by 14 bps YoY to 25.5%.

PAT declined by 215 bps YoY to ₹46 crore.

Zero Base Merchandising (ZBM) implemented in 146 stores, reducing lines by 40% and inventories by 25%.

Floatz continued its growth trajectory at almost 40% plus.

Number of clients overall across the network reduced by almost 30% year-on-year.

Inventory agility improved with a 16% drop and aged inventory reduced by 30% to 35% lower.

Franchise stores stand at about 625, and key retail outlets expanded to almost 1,400.

NPS stands at a high of 85.

Revenue from operations increased YoY from ₹54.71 crore to ₹63.91 crore.

The company reported a net loss of ₹4.82 crore, a significant decline from the previous year's net profit of ₹29.42 crore.

The company's net worth is negative ₹28.67 crore, indicating a material uncertainty related to going concern.

The auditor has issued an unmodified opinion but has emphasized the going concern uncertainty.

The management plans to meet financial obligations through cash flows from operations, future business plans, and fund infusion by promoters.

The Government of Gujarat has registered the Company as a viable sick unit and granted various relief and concessions.

The company has unutilized incentive of Rs. 4,173.36 lacs from the state government.

The company has accounted for Rs.736.51 lacs pertaining to claims that have been submitted to the state government, and grouped under the head other income in the quarter ending March 2025.

FY'25 revenue increased by 32% YoY to ₹2,910 crore.

Q4 FY'25 revenue increased by 21% YoY to ₹747 crore.

EBITDA margin for Q4 FY'25 stood at 7%.

Ethanol volumes increased by 51% YoY in FY'25.

150 KLPD expansion at Bathinda is progressing well and expected to be commissioned by December 2025.

75 KLPD biodiesel plant is expected to be commissioned in July 2025.

Edible oil business is being phased out.

Company expects margin improvement in the distillery business due to softening raw material prices.

Working capital of INR 90 crores utilized for the edible oil business has been adjusted with the bank.

FY25 revenue declined 2.8% YoY to ₹3,675 crore due to market dynamics and geopolitical uncertainties.

EBITDA margin softened to 13.7% due to pressures on realization rates, higher raw material costs, and inflation.

Turnaround to PAT of ₹203 crore supported by discipline, execution, and cost controls.

Net debt reduced by 53% to a net debt to EBITDA ratio of 0.3x.

Strategic focus on innovation, customer engagement, and agile execution.

Scaling up R&D initiatives and advancing digitalization for next-generation refractory solutions.

Investing CAPEX to maximize cost competitiveness through circular economy initiatives.

Expect increased growth for FY26 coupled with margin improvement driven by stronger domestic demand and cost optimization.

Transcript of the conference call held on May 28, 2025, is now available.

The conference call discussed audited financial results for the year ended March 31, 2025.

The announcement complies with SEBI regulations.

The transcript can be accessed via the provided link: https://olectra.com/wp-content/uploads/AxisCap-Olectra-May28-2025.pdf